Oncolytics Biotech (TSE:ONC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oncolytics Biotech reported positive results for its pelareorep and paclitaxel combination, showing significant improvements in survival rates for metastatic breast cancer patients. The company, with a solid cash position, plans to advance to a registration-enabling study. Oncolytics’ financial stability and promising clinical data suggest potential growth in the oncology sector.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
